Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong John Kastelein?

John J.P. Kastelein

Member, Department of Vascular Medicine

University of Amsterdam

HQ Phone:  +31 20 525 2704

Direct Phone: +31 ** *** ****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Amsterdam

Spui 21

Amsterdam, North Holland,

Netherlands

Find other employees at this company (10,226)

Background Information

Employment History

Collector and Senior Collector

BankBoston


Renewal Analyst

Bank of Boston


Documentation Analyst

Bank of Boston


Credit Information Analyst III

Bank of Boston


Employee Benefits Coordinator

Bank of Boston


Home Health Aide Placement Supervisor

BOSTON VISITING NURSE ASSOCIATION


Affiliations

Michigan Life Therapeutics LLC

Medical Advisory Board Member


Mazal Plant Pharmaceuticals Inc

Clinical Advisory Board Member


European Atherosclerosis Society

Member


The International Atherosclerosis Society incorporated

Executive Board


Captivate Network Inc

Number of Executive and Steering Committees


European Society of Cardiology

Fellow


Cerenis Therapeutics SA

Scientific Advisory Board Member


gemphire therapeutics inc.

Medical Advisory Board Member


Forbion Capital Partners

Advisor


Royal Dutch Society for Medicine & Physics

Member


International Task Force for CHD Prevention

Board Member


Council for Basic Science of the American Heart Association

Member


ENHANCE

Number of Executive and Steering Committees


IDEAL

Number of Executive and Steering Committees


RADIANCE

Number of Executive and Steering Committees


ILLUMINATE

Number of Executive and Steering Committees


TNT

Number of Executive and Steering Committees


JUPITER

Number of Executive and Steering Committees


Dezima Pharma BV

Founder


Xenon Genetics Inc.

Founder


uniQure N.V.

Co-Founder


Synexus Limited

Senior Medical Advisor In Lipid Metabolism Clinical Research


Large Pharma

Advisor


CATABASIS PHARMACEUTICALS INC

Scientific Advisory Board Member


Lipid Sciences , Inc.

Founder


Omthera Pharmaceuticals , Inc.

Member of Scientific Advisory Board


STICARES INTERACT

Scientific Advisory Board Member


The Cleveland Clinic Foundation

Board Member


Activity

Board Member


Amsterdam Molecular Therapeutics

Founder


Aegerion Pharmaceuticals, Inc.

Chairman of Aegerion's European Scientific Advisory Board


LifeCycle Pharma Inc

Scientific Advisory Boards Member


Heinrich Wieland Preize

Board Member


Symphony Dynamo , Inc.

Independent Board Member


AtheroNova Inc.

Member of the Medical Advisory Board


NewsRx LLC

Member, Scientific Advisory Board


Education

M.D.


M.D.

Univ. of Amsterdam


Web References(132 Total References)


Editorial Board

www.HDLforum.org [cached]

Dr John Kastelein
Chairman Department of Vascular Medicine University of Amsterdam


PACE - Physicians's Academy for Cardiovascular Education

www.pace-cme.org [cached]

Prof John J.P. Kastelein - Academic Medical Center, Amsterdam, The Netherlands


Gemphire | Advisory Board

www.michiganlifetherapeutics.com [cached]

John Kastelein
John Kastelein Dr. Kastelein is a Medical Advisory Board member for Gemphire. Dr. Kastelein is Professor of Medicine, Chairman of the Department of Vascular Medicine, and Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. In 2014, he was the Robert Levy Memorial Lecturer at American Heart Association Scientific Sessions. Dr. Kastelein has published over 740 research papers and he was one of the 3000 Highly Cited Researchers in 2014.


Mazal Pharm

mazalpharmaceutical.com [cached]

John J.P. Kastelein (1954) is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease.
He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.


CETP as a Therapeutic Target | NLA vClinic

lipid.realcme.com [cached]

John J.P. Kastelein, MD PhD, FESC
Professor of Medicine Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam John J.P. Kastelein, MD PhD, FESC John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr. Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology. Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008. Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment ofhypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72. Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease. Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet. Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has lead to the recognition of the AMC as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the set up of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject. Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal. He has directed 47 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory